Материалов:
1 005 012

Репозиториев:
30

Авторов:
761 409

По вашему запросу найдено документов: 49726

Страница 1 из 4973

Determination of EGFR gene somatic mutations in tissues and plasma of patients with advanced non-small cell lung cancer
Brovkina O., Gordiev M., Toropovskiy A., Khodyrev D., Enikeev R., Gusev O., Shigapova L., Nikitin A.
, and increases metastatic ability; it has a significant impact on the choice of medical therapy of non-small cell
Lobe-specific metastasis in non-small cell lung cancer
Aksarin A.A., Ter-Ovanesov M.D., Mordovsky A.A., Kopeyka S.M., Troyan P.P.
Aim: to identify the pathways of lymph node metastases in non-small cell lung cancer (NSCLC
Распространенность вируса папилломы человека у больных немелкоклеточным раком легкого
Гаптулбарова, Ксения Андреевна, Долгашева, Дарья Сергеевна, Ибрагимова, Марина Константиновна
lung cancer (NSCLC). The study included 109 patients with primary operable non-small cell lung cancer
LONG-TERM OVERALL AND RELAPSE-FREE SURVIVAL IN A PATIENT WITH METASTATIC NON-SMALL CELL LUNG CANCER TREATED WITH IMMUNOTHERAPY. A CASE REPORT
Afonin G.V., Skoropad V.Yu., Glukhareva A.E., Kupriyanova E.I., Agababyan T.A., Ivanov S.A., Kaprin A.D.
rates of recurrence in patients with stage I–III non-small cell lung cancer (NSCLC), even after radical
Determination of EGFR gene somatic mutations in tissues and plasma of patients with advanced non-small cell lung cancer
Brovkina O., Gordiev M., Toropovskiy A., Khodyrev D., Enikeev R., Gusev O., Shigapova L., Nikitin A.
, and increases metastatic ability; it has a significant impact on the choice of medical therapy of non-small cell
Targeted therapy of brain metastases in patients with ALK-positive non-small cell lung cancer: A review
Sakaeva, D.D., Bulavina, I.S., Сакаева, Д.Д., Булавина, И.С.
Targeted therapy of brain metastases in patients with ALK-positive non-small cell lung cancer: A
Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)
Topchu I., Karnaukhov N., Mazitova A., Yugai V., Voloshin M., Tikhomirova M., Kit O., Frantsiyants E., Kharin L., Airapetova T., Ratner E., Sabirov A., Abramova Z., Serebriiskii I., Boumber Y., Deneka A.
assessed MSI2 as a potential clinical biomarker in non-small cell lung cancer (NSCLC). Methods: The current
SURVIVAL AFTER SURGICAL TREATMENT OF SYNCHRONOUS METASTATIC LESION OF THE ADRENAL TUMORS
Muradyan A., Kostin A., Tolkachev A., Vorobyev N.
significantly greater survival in patients with renal cell carcinoma compared to non-small cell lung cancer
Pharmacoeconomic aspects of oral vinorelbine application: A budget impact analysis considering the new registered price
Ivanov D.А., Dyakov I.N., Zyryanov S.К.
for each patient with stage IV non-small-cell lung cancer compared with the use of pemetrexed, and 558
Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
Bodor J., Boumber Y., Borghaei H.
© 2019 American Cancer Society The emergence of immunotherapy has dramatically changed how non–small-cell

Страница 1 из 4973

Фасеты

Партнеры

КФУ
ТГУ
Elpub
СФУ
Webpublishers

Индексация

BASE
WorldCat
OpenAIRE
EDS
core